Caixa Capital Risc rebrands as Criteria Capital Risc

13 July 2026

Barcelona, Spain-based CriteriaCaixa, the holding company that manages the business assets of ‘la Caixa’ Banking Foundation, today announces a reboot of its start-up investment business to facilitate the growth of science and technology-based high-potential emerging companies.

Through its two funds, Criteria Bio Ventures and Criteria Venture Tech, it plans to invest 300 million euros ($343 million) in innovative early-stage companies, to promote transformative therapies and technologies that can have a positive impact on society, prioritizing long-term value creation. Investments will primarily be focused on Spain and Portugal, and selectively on Europe and North America. Investments in Spain represent nearly 70% of the current portfolio's value, reflecting the company’s strong commitment to developing the country's business and innovation ecosystem.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Biotechnology